Efficacy data of ICLUSIG (ponatinib) in CP-CML

Explore ICLUSIG efficacy in chronic phase chronic myeloid leukemia

Long-term efficacy data across two pivotal trials in heavily pretreated and TKI-resistant CP-CML patients.1-3

ICLUSIG efficacy in CP-CML is supported by two pivotal trials: OPTIC, which established a response-based dose-reduction strategy in patients resistant to at least 2 prior TKIs or with the T315I mutation,1-3 and PACE, which provides long-term follow-up data in heavily pretreated patients.1

In the OPTIC 45 mg → 15 mg cohort, more than half of patients had a response by 5 years.2-4 In PACE, ICLUSIG provided durable, clinically meaningful responses in TKI-resistant CP-CML patients, including those with the T315I mutation.1

Ponatinib (ICLUSIG) is recommended as a treatment option by NCCN treatment guidelines for certain patients with T315I mutation.2,4

OPTIC trial efficacy data of ICLUSIG in CP-CML

PACE trial efficacy data of ICLUSIG in CP-CML

CP-CML=chronic-phase chronic myeloid leukemia; NCCN=National Comprehensive Cancer Network®; TKI=tyrosine kinase inhibitor

View ICLUSIG safety profile in CML

View ICLUSIG dosing optimization in CML

CML Patient Profiles

""

CML resources and support

""